GlobeNewsWire · ADC · October 25, 2026

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

Get the app for more

Explore stock news, insights and company research.